Small Molecule Decoys of Aggregation for Elimination of Aβ-Peptide Toxicity
Open Access
- 14 April 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 14 (9) , 1575-1584
Abstract
Several lines of evidence suggest that a characteristic of the neuropathology of Alzheimer's disease (AD) is the aggregation of the amyloid beta peptides (Aβ), fragments of the human amyloid precursor protein (hAPP). The dominating species are the Aβ40 and Aβ42 fragments with 40 and 42 amino acids, respectively. Aβ initially forms soluble oligomers that continue to expand to protofibrils, suggestively the neurotoxic intermediates, and thereafter turn into insoluble fibrils that are markers of the disease. Using the powerful tool of pharmacophore simulation, we selected small molecules not known to possess central nervous system (CNS) activity but that might interact with Aβ aggregation, from the NCI Chemotherapeutic Agents Repository, Bethesda, MD. We assessed the activity of these compounds on Aβ aggregation using the thioflavin T fluorescence correlation spectroscopy (ThT-FCS) assay. Förster resonance energy transfer-based fluorescence correlation spectroscopy (FRET-FCS) was used to characterize the dose-dependent activity of selected compounds at an early stage of Aβ aggregation. Transmission electron microscopy (TEM) confirmed that the interfering substances block fibril formation and identified the macrostructures of Aβ aggregates formed in their presence. We first found three compounds generating protofibrils with branching and budding never observed in the control. One compound generated a two-dimensional sheet structure and another generated a double-stranded filament. Importantly, these compounds generating protofibrils with altered macrostructure protected against Aβ-induced toxicity in a cell model while showing no toxicity in a model of cognition in normal mice. The data suggest that the active compounds act as decoys turning the aggregation into nontoxic trajectories and pointing toward novel approaches to therapy.Keywords
Funding Information
- Vetenskapsr?det (2022-03402, VR 2018-05337)
- Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering
- Stiftelsen f?r Strategisk Forskning (SBE13-0115)
- Olav Thon Stiftelsen
- Strategic Research Program in Neuroscience STRATNEURO
This publication has 31 references indexed in Scilit:
- BRICHOS Domains Efficiently Delay Fibrillation of Amyloid β-PeptideJournal of Biological Chemistry, 2012
- Aβ oligomer toxicity inhibitor protects memory in models of synaptic toxicityBritish Journal of Pharmacology, 2012
- Elucidation of common pharmacophores from analysis of targeted metabolites transported by the multispecific drug transporter—Organic anion transporter1 (Oat1)Bioorganic & Medicinal Chemistry, 2011
- Small Molecule Microarrays Enable the Discovery of Compounds That Bind the Alzheimer’s Aβ Peptide and Reduce its CytotoxicityJournal of the American Chemical Society, 2010
- Direct characterization of amyloidogenic oligomers by single-molecule fluorescenceProceedings of the National Academy of Sciences, 2008
- Polymorphism in the intermediates and products of amyloid assemblyCurrent Opinion in Structural Biology, 2007
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002
- The nuclear poly(A) binding protein, PABP2, forms an oligomeric particle covering the length of the poly(A) tailJournal of Molecular Biology, 2000
- Amyloid β-peptide polymerization studied using fluorescence correlation spectroscopyChemistry & Biology, 1999
- Binding of flexible ligands to macromoleculesNature, 1975